From Complaint to Reporting: The New Operational Workflow of the Italian Ministry of Health
With Circular No. 59712 of 21 July 2026, the Italian Ministry of Health introduced a new digital system for managing…
Focus
Published the 22nd AIFA National Report 2025 on Clinical Trials of Medicinal Products in Italy
The 22nd AIFA National Report 2025 on Clinical Trials of Medicinal Products in Italy provides an updated snapshot of the…
Implantable devices and class III devices: Delegated Regulation (EU) 2026/1451
With the publication of Delegated Regulation (EU) 2026/1451, the European Commission expands the list of implantable devices and class III…
National HTA Medical Device Program (PNHTA‑MD) 2026–2028
Technological innovation must advance hand in hand with sustainability and clinical validation. This Focus examines the National HTA Programme for…
The ecosystem of medical device development: the strategic role of Early Feasibility Studies (EFS)
Within the complex and dynamic ecosystem of medical device development, innovation cannot advance without a solid and timely clinical strategy.…
Drug Negotiation Renewed: Introduction of “Simplified” and “Fast Track” Procedures
The Italian Medicines Agency (AIFA) has recently adopted the new “Document for the Harmonization of Procedures for Simplifying the Price…
Update of the Guidelines for the Preparation of the Price and Reimbursement Dossier for a Medicinal Product
Following the publication of the Regulation governing the organization and functioning of the Scientific and Economic Commission (CSE), adopted by…
Update of the Guidelines for the preparation of the pricing and reimbursement dossier of a medicinal product
With Determination DTS No. 88/2025 of 23 December 2025, AIFA published an update to the ‘Guidelines for the preparation of…
Dialogue with the CSE: modalities and procedures for hearings
AIFA has published the procedures for requesting a hearing before the Scientific and Economic Commission for Medicines (CSE). Companies, scientific…
Pharmaceutical sector in evolution: objectives of the Consolidated Act
The main objectives of the measure are to improve access to medicines, optimise the regulatory framework governing the provision of…